BCR-ABL-transduced human cord blood cells produce abnormal populations in immunodeficient mice

Leukemia

Volumn 19, Issue 3, 2005, Pages 442-448

  Chalandon, Y ^a,b   Jiang, X ^a   Christ, O ^a   Loutet, S ^a   Thanopoulou, E ^a   Eaves, A ^a   Eaves, C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

BCR ABL; Gene transfer; Leukemogenesis; NOD SCID mice

Indexed keywords

BCR ABL PROTEIN; BETA 2 MICROGLOBULIN; GREEN FLUORESCENT PROTEIN; CD34 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL POPULATION; CELL TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DISEASE COURSE; ERYTHROID CELL; FLOW CYTOMETRY; GENE TRANSFER; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKOCYTE COUNT; MEGAKARYOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SOUTHERN BLOTTING; SPLENOMEGALY; UMBILICAL CORD BLOOD; WESTERN BLOTTING; ANIMAL; CANCER TRANSPLANTATION; CELL DIVISION; CYTOLOGY; DISEASE MODEL; EXPERIMENTAL LEUKEMIA; FETUS BLOOD; GENE VECTOR; GENETICS; IMMUNOLOGY; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD34; CELL DIFFERENTIATION; CELL DIVISION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FETAL BLOOD; FUSION PROTEINS, BCR-ABL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LEUKEMIA, EXPERIMENTAL; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION;

EID: 15044346433     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403650     Document Type: Article

References (25)

1. Groffen J, Stephenson JR, Heisterkamp N, De Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93-99.
2. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315: 550-554.
3. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212-214.
4. Konopka JB, Witte ON. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 1985; 5: 3116-3123.
5. Van Etten RA, Jackson P, Baltimore D. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 1989; 58: 669-678.
6. Van Etten RA. Retroviral transduction models of Ph+ leukemia: advantages and limitations for modeling human hematological malignancies in mice. Blood Cells Mol Dis 2001; 27: 201-205.
7. 2 microglobulin-null mice. J Clin Invest 2001; 107: 199-206.
8. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996; 7 1405-1413.
9. BCR-ABL activity in transduced primary human hematopoietic cells controls lineage reprogramming. Blood 2002; 99: 3197-3204.
10. Hennemann B, Conneally E, Pawliuk R, Leboulch P, Rose-John S, Reid D et al. Optimization of retroviral-mediated gene transfer to human NOD/SCID mouse repopulating cord blood cells through a systematic analysis of protocol variables. Exp Hematol 1999; 27: 817-825.
11. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA 1999; 96: 12804-12809.
12. 2-microglobulin-deficient NOD-scid mice. J Immunol 1997; 158: 3578-3586.
13. Jiang X, Ng E, Yip C, Eisterer W, Chalandon Y, Stuible M et al. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo. Blood 2002; 100: 3731-3740.
14. Conneally E, Cashman J, Petzer A, Eaves C. Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice. Proc Natl Acad Sci USA 1997; 94: 9836-9841.
15. Bhatia M, Wang JCY, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA 1997; 94: 5320-5325.
16. Raskind WH, Fialkow PJ. The use of cell markers in the study of human hematopoietic neoplasia. Adv Cancer Res 1987; 49: 127-167.
17. Verstegen MMA, Cornelissen JJ, Terpstra W, Wagemaker G, Wognum AW. Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice. Leukemia 1999; 13: 618-628.
18. Eisterer W, Jiang X, Christ O, Glimm H, Lee K, Pang E et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 2005; 19: 435-441.
19. Eaves CJ, Eaves AC. Progenitor cell dynamics. In: Carella AM, Daley GQ, Eaves CJ, Goldman JM, Hehlmann R (eds). Chronic Myeloid Leukemia: Biology and Treatment. London: Martin Dunitz, 2001, pp 73-100.
20. 1-positive chronic myelogenous leukemia. Ann Intern Med 1975; 83: 820-823.
21. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 1975; 45: 321-334.
22. Collins SJ, Groudine MT. Rearrangement and amplification of c-abl sequences in the human chronic myelogenous leukemia cell line K-562. Proc Natl Acad Sci USA 1983; 80: 4813-4817.
23. Andersson LC, Jokinen M, Gahmberg CG. Induction of erythroid differentiation in the human leukaemia cell line K562. Nature 1979; 278: 364-365.
24. Neumann F, Herold C, Hildebrandt B, Kobbe G, Aivado M, Rong A et al. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol 2003; 70: 1-10.
25. Moravcova J, Zmekova V, Klamova H, Voglova J, Faber E, Michalova K et al. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase. Leukemia Res 2004; 28 415-419.